Novelix Pharmaceuticals Limited has submitted its quarterly compliance certificate under SEBI (Depositories and Participants) Regulations, 2018 to BSE Limited for the quarter ended March 31, 2026. The certificate demonstrates the company's adherence to mandatory regulatory requirements for securities dematerialisation processes.

Regulatory Compliance Certificate

The certificate was issued by Venture Capital and Corporate Investments Private Limited, serving as the company's Registrar and Share Transfer Agent (R&T Agent). The document was submitted to BSE Limited on April 9, 2026, and signed by Venkateshwarlu Pulluru, Whole-time Director of Novelix Pharmaceuticals Limited.

Dematerialisation Process Confirmation

The R&T Agent certified that securities received for dematerialisation have been properly mutilated and cancelled after due verification. The certificate confirms that the names of both depositories - National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL) - have been updated in the company's records as registered owners within the mandated 15-day period.

The certification process ensures that valid Dematerialisation Request Forms (DRF) and share certificates were processed according to regulatory guidelines. Details of the securities have been furnished to the relevant stock exchanges as required under the regulations.

Company Information

Novelix Pharmaceuticals Limited, formerly known as Trimurthi Limited , operates from its registered office in Hyderabad, Telangana. The company maintains its corporate identification number as L67120TG1994PLC018956 and trades under the scrip symbol NOVELIX on stock exchanges.

The submission of this quarterly certificate represents standard regulatory compliance, ensuring transparency in the dematerialisation process and maintaining accurate depository records for investor protection.

Novelix Pharmaceuticals Limited (formerly Trimurthi Limited) has filed mandatory disclosures under SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following the allotment of 11,50,000 equity shares through warrant conversion to promoter group entities.

Warrant Conversion and Share Allotment

The board approved the allotment of 11,50,000 equity shares with a face value of Rs. 10.00 each at an issue price of Rs. 20.00 per share, including a premium of Rs. 10.00 per share. This allotment resulted from warrant holders exercising their conversion option, with warrant holders paying the remaining 75% of the issue price (Rs. 15.00 per warrant).

The warrant conversion was part of a larger preferential issue of 15,000,000 warrants originally allotted on January 10, 2025. The warrants were issued following a special resolution passed at an Extra-Ordinary General Meeting on November 18, 2024, with in-principle approval from BSE Limited received on December 31, 2024.

SEBI Disclosure Requirements

The company has submitted detailed disclosures under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, documenting the substantial acquisition by promoter group entities. The disclosure provides comprehensive shareholding details before and after the acquisition.

Impact on Share Capital Structure

Following the allotment, the company's shareholding pattern has been significantly altered, with the combined promoter group holding increasing substantially.

Director Resignation

Concurrently, the board approved the resignation of Mr. Jivamohan Divakar Valluri (DIN: 09218013), Non-Executive Director, effective from March 30, 2026. Valluri cited pre-occupation and personal commitments as reasons for stepping down from his positions including memberships in Audit Committee and Nomination & Remuneration Committee.

Regulatory Compliance

Both the share allotment and SEBI disclosures were made in compliance with applicable regulations. The company has submitted all required documentation to BSE Limited, with the intimation signed by Venkateshwarlu Pulluru, Whole-time Director (DIN: 02076871), who also serves as Designated Partner for SRINIDHI FINE-CHEMICALS LLP.